Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma

SUMMARY Cytotoxic T cells play an important role in graft‐versus‐host‐disease (GvHD) and graft‐versus‐leukaemia/myeloma, which may occur in patients treated with an allogeneic stem cell transplantation (ASCT). Here, we describe the selection of a myeloma reactive CD4+ cytotoxic T cell‐line (CTL) and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental immunology 2003-02, Vol.131 (2), p.340-346
Hauptverfasser: HOLLOWAY, P. A., KALDENHOVEN, N., KOK‐SCHOEMAKER, H. M., VAN KESSEL, B., VAN BLOKLAND, W. T. M., BLOEM, A. C., LOKHORST, H. M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:SUMMARY Cytotoxic T cells play an important role in graft‐versus‐host‐disease (GvHD) and graft‐versus‐leukaemia/myeloma, which may occur in patients treated with an allogeneic stem cell transplantation (ASCT). Here, we describe the selection of a myeloma reactive CD4+ cytotoxic T cell‐line (CTL) and two CD4+ clones from this CTL. The CTL was generated from the blood from a patient with multiple myeloma (MM) with graft versus myeloma/GvHD, following an ASCT. The CTL was stimulated using irradiated peripheral blood mononuclear cells and EBV transformed B cells from the myeloma patient (EBVp), both of which were obtained prior to ASCT. Both the CTL and the two T cell clones specifically lysed EBVp and secreted IFN‐γ after coculture with EBVp and autologous myeloma tumour cells in a class II restricted fashion. These results show that myeloma tumour cells and autologous B cells present a common polymorphic peptide that functions as a target for graft derived cytotoxic T cells. Identification of these proteins will give insight into the relationship between graft versus myeloma (GvM) and GvHD and may provide immunotherapeutical targets in the treatment of MM.
ISSN:0009-9104
1365-2249
DOI:10.1046/j.1365-2249.2003.02067.x